Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2001
05/30/2001EP1102588A1 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
05/30/2001EP1102586A1 Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
05/30/2001EP1102583A2 Treatment of addiction and addiction-related behavior
05/30/2001EP1102535A2 Compounds and methods
05/30/2001EP0925067A4 Composition and method for repairing neurological tissue
05/30/2001EP0752992B1 IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
05/30/2001EP0750616B1 Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
05/30/2001EP0687176B1 Use of riluzole for treating aids-related neural disorders
05/30/2001EP0641320B1 Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
05/30/2001EP0637306B1 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy
05/30/2001CN1297454A Novel omega-conotoxin peptides
05/30/2001CN1297448A Paroxetine ascorbate
05/30/2001CN1297441A Heterocyclically substd. amides used as calpain inhibitors
05/30/2001CN1297439A 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
05/30/2001CN1297436A Substd. pyrrolidine hydroxamate metalloprotease inhibitors
05/30/2001CN1297432A Substd. amides, their production and their use
05/30/2001CN1297431A Phenylsulfonamide-phenylethylamines useful as dopamine receptors
05/30/2001CN1297354A Dipeptide caspase inhibitors and use thereof
05/30/2001CN1296848A Medicine for treating primary menalgia
05/30/2001CN1296841A Extract of Chinese-medicinal herbs and its application
05/30/2001CN1066449C Tricyclic oxime ethers, processes for their preparation and pharmaceutical compositions contg. them
05/30/2001CN1066445C Aroyl-piperidine derivs.
05/30/2001CN1066343C Process for preparation of liver protecting and drunkenness dispelling liquid medicine
05/30/2001CN1066336C Pharmaceutical composition for treatment of alcohol addiction
05/30/2001CN1066330C Bear bile products and preparation process
05/29/2001US6239288 Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis
05/29/2001US6239267 Nucleotide sequence of ion channel protein associated with capsaicin; diagnosis and treatment of nervous system disorders, incontinence, stroke; antiischemic agents; antiarthritic/antiinflammatory agents; analgesics
05/29/2001US6239181 Method for preventing and treating peripheral neurophathy by administering selegiline
05/29/2001US6239180 Transdermal therapeutic device and method with capsaicin and capsaicin analogs
05/29/2001US6239179 N-aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands
05/29/2001US6239173 Antiinflammatory, antipyretic, analgesic, and antiarthritic agents
05/29/2001US6239165 Liquid pharmaceutical formulation containing zotepine
05/29/2001US6239156 Reduction of glutamate neurotoxicity by the administration of the neuroprotectant riluzole,
05/29/2001US6239155 Phenyl-substituted 1,4-dihydropyridines
05/29/2001US6239147 To treat cns, gastrointestinal and other disorders. substance p antagonists having improved activity and fewer side effects, treatment of emesis induced by antineoplastic agents, isochroman ring
05/29/2001US6239146 Neurotrophic difluoroamide agents
05/29/2001US6239135 Arylpiperazines having activity at the serotonin 1A receptor
05/29/2001US6239134 Diazole derivatives as serotonergic agents
05/29/2001US6239129 Characterised by an indole ring on the aromatic moiety by a cyano group and on the indole nitrogen by an aminoalkyl chain. great affinity for 5-ht2c receptors, useful for depression, panic attacks, obsessive-compulsive disorders, phobias,
05/29/2001US6239128 Combating diseases and disorders associated with or mediated by the release of excitatory amino acids, associated with reduced blood flow to the brain and other cns tissue,
05/29/2001US6239111 Drug for treating brain diseases, enables prevention or treatment of dementia and similar diseases caused by degeneration or sloughing of neurons, an ally sulfide, sulfoxide or sulfone
05/29/2001US6239107 Treatment of male impotence or treatment of neurodegenerative diseases
05/29/2001US6239102 Concentrate comprising, as active agent, (3'-desoxy-3-oxo-mebmc)1-(val)2-cyclosporin, stabilizer selected from oleic acid or palmitoyl oleoyl phosphatidyl glycerol or salts thereof, ethanol
05/29/2001US6238883 Neurotransmitter transporter SC6
05/29/2001US6238859 Virus protein antigens of the JC virus
05/29/2001US6238689 Intestinal absorption of nicotine to treat nicotine responsive conditions
05/29/2001CA2195923C Azetidines
05/29/2001CA2171638C The semaphorin gene family
05/29/2001CA2091506C Thieno[3,2-b]pyridine derivatives
05/25/2001WO2001036641A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
05/25/2001WO2001036626A2 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
05/25/2001WO2001036618A2 Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced
05/25/2001WO2001036610A1 Human enzymes of the metalloprotease family
05/25/2001WO2001036605A2 2786, a human aminopeptidase
05/25/2001WO2001036602A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
05/25/2001WO2001036487A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
05/25/2001WO2001036483A1 Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders
05/25/2001WO2001036454A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals
05/25/2001WO2001036450A1 S-allylmercaptoglutathione and uses thereof
05/25/2001WO2001036440A1 23 human secreted proteins
05/25/2001WO2001036428A1 Silylated heterocyclic compounds
05/25/2001WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors
05/25/2001WO2001036423A1 Spiro(2h-1-benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors
05/25/2001WO2001036422A1 Tricyclic dihydropyrimidine potassium channel openers
05/25/2001WO2001036419A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
05/25/2001WO2001036417A1 New use and novel n-azabicyclo-amide derivatives
05/25/2001WO2001036407A1 Novel amidine derivatives, preparation and use thereof as medicines
05/25/2001WO2001036403A1 Urea derivatives as anti-inflammatory agents
05/25/2001WO2001036398A1 Benzoxa- and benzthiazoles
05/25/2001WO2001036388A1 Aza compounds having neuronal activity
05/25/2001WO2001036375A1 Aminoalcohol derivatives useful for the treatment of gastrointestinal disorders
05/25/2001WO2001036360A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
05/25/2001WO2001036005A2 Targeted delivery of therapeutic and diagnostic moieties
05/25/2001WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration
05/25/2001WO2001035948A2 Neurophilin ligands for treating ocular conditions
05/25/2001WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion
05/25/2001WO2001035942A2 Analgesic compositions containing buprenorphine
05/25/2001WO2001035939A2 Oleamide in epilepsy
05/25/2001WO2001013909A3 Compositions and methods for treating opiate intolerance
05/25/2001WO2001013905A3 Methods for the treatment of mental and vascular disorders
05/25/2001WO2001011085A3 Bdnf polymorphism and association with bipolar disorder
05/25/2001WO2001007023A3 Azetidine compounds in cns and eye diseases
05/25/2001WO2001004349A3 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
05/25/2001WO2000064426A3 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug
05/25/2001WO2000059489A3 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
05/25/2001WO2000032555A8 Derivatives of (+)-venlafaxine and methods of preparing and using the same
05/25/2001CA2396428A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
05/25/2001CA2392076A1 Human enzymes of the metalloprotease family
05/25/2001CA2391969A1 S-allylmercaptoglutathione and uses thereof
05/25/2001CA2391598A1 Novel amidine derivatives, preparation and use thereof as medicines
05/25/2001CA2391450A1 Targeted delivery of therapeutic and diagnostic moieties
05/25/2001CA2391291A1 Tricyclic dihydropyrimidine potassium channel openers
05/25/2001CA2391087A1 Imidazole compounds as phosphodiesterase vii inhibitors
05/25/2001CA2390071A1 Aza compounds having neuronal activity
05/25/2001CA2390031A1 Double-stranded rna receptor (dsrna-r) and methods relating thereto
05/25/2001CA2389662A1 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
05/25/2001CA2389604A1 New use and novel n-azabicyclo-amide derivatives
05/25/2001CA2388922A1 23 human secreted proteins
05/25/2001CA2387809A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
05/25/2001CA2386579A1 Neurophilin ligands for treating ocular conditions